Cancer's heterogeneous nature presents significant challenges in unraveling its genetic basis and translating this knowledge into effective personalized medicine. While genomic sequencing has revolutionized our understanding of cancer's driver mutations, translating this information into targeted therapies faces hurdles.  Identifying truly actionable mutations amidst passenger mutations remains a critical challenge, complicated by inter-tumoral and intratumoral heterogeneity.  Furthermore, the complex interplay between genetic alterations, epigenetic modifications, and the tumor microenvironment necessitates a holistic approach beyond single-gene analyses.  Experimental limitations include the difficulties in accurately modelling complex tumor ecosystems *in vitro* and *in vivo*, hindering the predictive power of preclinical studies.  The ethical considerations surrounding the cost and accessibility of comprehensive genomic profiling for all cancer patients further complicate the widespread implementation of personalized medicine.  Overcoming these challenges requires advances in high-throughput screening technologies, the development of more sophisticated computational models integrating multi-omics data, and improved strategies for validating preclinical findings in diverse patient populations.  Addressing these issues is crucial to unlock the full potential of personalized cancer therapies.